BioSpace News Archive

BioCardia®, Inc. [Nasdaq: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today reported financial results for the fourth quarter and full year ended December 31, 2019 and recent business highlights, and filed its annual 10-K with the Securities and Exchange Commission.

Association deepens commitment to its lung infection resources and research program to address COVID-19 and respiratory virus breakthroughs

Eaton leverages manufacturing expertise, 3D printing capabilities to rapidly develop face shields and help address critical protective equipment shortages

Pharmazz, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat patients in critical care, today announced that centhaquine, a drug in final stage of development, can provide hemodynamic stability, improve tissue oxygenation, reduce pulmonary edema, reduce acute respiratory distress syndrome (ARDS),

Immunomic Therapeutics, Inc., a privately held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, announced today that it is developing a nucleic acid vaccine candidate against COVID-19 leveraging its investigational UNITE platform for prevention of the novel coronavirus disease caused by SARS-Cov-2 coronavirus.

AmerisourceBergen Corporation (NYSE: ABC) today announced that it plans to release its results for the Second Quarter Fiscal 2020 on Thursday, May 7, 2020, prior to the opening of trading on the New York Stock Exchange.

Phathom Pharmaceuticals, Inc. announced that company management will participate in one-on-one meetings at the upcoming 19th Annual Needham Virtual Healthcare Conference from Tuesday, April 14, 2020 through Wednesday, April 15, 2020.

BioCryst Pharmaceuticals, Inc. announced that the company has opened enrollment into a randomized, double-blind, placebo-controlled clinical trial to assess the safety, clinical impact and antiviral effects of galidesivir in patients with COVID-19.

Simulations Plus, Inc., the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, reported financial results for its second quarter of fiscal year 2020, the period ended February 29, 2020.

The nCoup Investigational Drug System is being used by clinical researchers on dozens of clinical trials to study possible drugs or vaccines to address the COVID-19 pandemic.